Two colleagues work at the same company, eat lunch from the same deli, exercise a few times a week, and don’t smoke. One has a heart attack at 52. The other is still running 5Ks at 70. Their cholesterol numbers were never dramatically different. Their blood pressure readings were in similar ranges. From a standard clinical standpoint, they looked like similar risks. But they weren’t — and the difference was largely written in their genes before either of them made a single lifestyle choice.
Heart disease is the leading cause of death in the United States and most of the developed world, responsible for roughly one in three deaths annually. Most of what medicine currently does to prevent it involves measuring blood markers — cholesterol, blood pressure, blood sugar, C-reactive protein — and managing those numbers with drugs and lifestyle recommendations. That approach has genuine value. It’s also incomplete. The numbers on a lab report don’t reveal the biological mechanisms driving them, and two people with identical numbers can have fundamentally different genetic risk architectures underneath.
Understanding the genetic layer of cardiovascular risk doesn’t replace cholesterol panels or blood pressure monitoring. It adds context that makes those measurements more meaningful — explaining why some people’s arteries accumulate plaque despite clean diet and exercise, why some people’s blood pressure resists standard treatment, why some families seem to have early heart disease in every generation regardless of how carefully the members live. That context, once known, changes what prevention actually looks like.
How Genetics Shapes Cardiovascular Risk — The Mechanisms That Matter
Cardiovascular disease is not one condition. It’s a family of conditions — coronary artery disease, stroke, heart failure, atrial fibrillation, venous thromboembolism, and others — that share some common pathways but also have distinct biological drivers. Genetics influences several of the most important ones.
Cholesterol metabolism is partly genetic. How efficiently the liver clears LDL particles from the bloodstream, how much cholesterol the body produces endogenously, how lipoproteins are assembled and transported — all of these processes involve enzymes and proteins encoded by genes with known variants. Blood pressure regulation is similarly genetic, involving the renin-angiotensin-aldosterone system, nitric oxide production in blood vessel walls, and sodium-potassium balance in the kidneys. Blood clotting tendency is genetic. Inflammation susceptibility is genetic. The structure and compliance of blood vessel walls is influenced by genetics.
None of this means lifestyle doesn’t matter — it does, enormously. But genetic variants set the baseline around which lifestyle operates. A person with favorable cholesterol genetics can tolerate a less perfect diet and still maintain healthy arterial walls. A person with unfavorable variants may do everything right and still face elevated risk. Knowing which situation applies determines what “doing everything right” actually needs to include.
APOE: The Cholesterol Clearance Gene
The APOE gene encodes apolipoprotein E, a protein that binds to LDL cholesterol particles and escorts them to the liver for clearance. It comes in three variants — e2, e3, and e4 — and every person inherits one copy from each parent. The e3 version is the most common and is considered neutral. The e4 variant, carried by roughly 25 percent of people with European ancestry, is significantly less effective at clearing LDL from the bloodstream.
People with one or two copies of APOE e4 can maintain what appears to be normal total cholesterol while LDL particles accumulate in their arteries, because the clearance mechanism is running below full efficiency. Dietary saturated fat has a more pronounced effect on LDL in APOE e4 carriers than in people with the e3 genotype — the same meal produces a larger and more sustained elevation. This partially explains why some people seem unusually sensitive to diet while others appear to eat freely without consequence.
APOE e4 is also the strongest known genetic risk factor for late-onset Alzheimer’s disease, which shares biological roots with cardiovascular disease — both involve impaired clearance of damaging proteins and lipids. For carriers, more aggressive LDL management and regular lipid particle testing (not just standard cholesterol panels) is often recommended by cardiologists familiar with the genotype.
ACE and NOS3: Blood Pressure From Two Directions
Blood pressure is regulated by a balance between forces that constrict blood vessels and forces that cause them to dilate. Two genes sit at key points on either side of this balance.
The ACE gene encodes angiotensin-converting enzyme, which activates angiotensin II — a hormone that constricts blood vessels and drives blood pressure up. The ACE gene carries a well-studied insertion/deletion polymorphism. People with the D/D genotype (deletion on both chromosomes) have higher baseline ACE activity, meaning their blood vessels tend to constrict more aggressively and their blood pressure runs higher as a result. D/D carriers may also develop more cardiac muscle mass in response to pressure load — a compensatory change that carries its own long-term risks. Critically, blood pressure medications that work by blocking ACE (ACE inhibitors) are particularly effective for D/D carriers, which is why genetic status can inform medication selection in ways that blood pressure readings alone cannot.
The NOS3 gene encodes endothelial nitric oxide synthase — the enzyme that produces nitric oxide in the lining of blood vessels. Nitric oxide causes blood vessels to relax and dilate. It’s also anti-inflammatory and anti-thrombotic, inhibiting platelet aggregation and reducing the tendency for clots to form. A common NOS3 variant (the Asp298 allele) reduces nitric oxide production, meaning blood vessels don’t dilate as effectively in response to exercise, blood flow demands, or temperature changes. People with this variant may find that their blood pressure doesn’t drop appropriately during physical activity, and their overall vascular flexibility is reduced. Dietary nitrates — found in leafy greens like spinach and arugula, and in beets — can partially compensate by providing a substrate the body converts to nitric oxide through a non-NOS3 pathway.
F5 Leiden and LPA: Clotting and Lipoprotein Risk
Heart attacks and strokes are often precipitated not by plaque alone but by blood clots forming on the surface of plaque. Genetic variants that affect clotting tendency therefore add a dimension of risk that sits on top of whatever the cholesterol picture shows.
The F5 gene encodes coagulation factor V. The Factor V Leiden variant — a single nucleotide change that makes factor V resistant to its normal deactivation signal — is one of the most common inherited thrombophilias in people of European descent, affecting roughly 5 percent of that population. It increases the risk of deep vein thrombosis and pulmonary embolism substantially, and in combination with other risk factors (oral contraceptives, prolonged immobility, surgery, pregnancy) the risk is amplified considerably. For cardiovascular events specifically, the implications depend on the overall risk profile, but F5 Leiden is something any comprehensive cardiovascular genetic assessment should include.
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose blood levels are almost entirely determined by genetics — specifically by variants in the LPA gene. Elevated Lp(a) is an independent risk factor for cardiovascular disease that operates through mechanisms distinct from standard LDL: it promotes inflammation in arterial walls, impairs clot dissolution, and contributes to plaque formation. Elevated Lp(a) affects an estimated 20 percent of the global population and is largely invisible to standard cholesterol panels, which don’t typically measure it. People with elevated Lp(a) who are told their cholesterol looks fine may be carrying significant cardiovascular risk that their routine testing simply isn’t capturing.
MTHFR and Homocysteine: The Cardiovascular Connection
Earlier in this series, the MTHFR gene was discussed in depth in the contexts of folate metabolism, methylation, and fertility. Its cardiovascular relevance adds another layer worth examining specifically. Elevated homocysteine — the compound MTHFR variants allow to accumulate when methylation is impaired — is an independent risk factor for heart attack and stroke, separate from cholesterol, blood pressure, or inflammation markers.
Homocysteine damages the endothelium, the thin layer of cells lining blood vessels, in ways that accelerate atherosclerosis. At elevated levels it promotes oxidative stress in vessel walls, impairs nitric oxide function, and increases clotting tendency. The damage accumulates silently over years. Standard cardiovascular panels don’t routinely include homocysteine testing, so the risk goes undetected unless specifically ordered.
For people with MTHFR C677T variants — particularly the TT (homozygous) genotype — the intervention is specific: switching from standard folic acid to methylfolate, using methylcobalamin instead of cyanocobalamin, and monitoring homocysteine levels as a biomarker of methylation function. This is a case where knowing the gene variant directly generates an actionable and measurable intervention that generic cardiovascular prevention recommendations would never produce.
What Standard Cardiac Testing Misses and Why Genetic Context Changes Prevention
A standard cardiac workup — fasting lipid panel, blood pressure measurement, maybe a stress test — captures snapshots. It measures outcomes, not mechanisms. It tells a person their LDL is 140, but not whether that LDL is being cleared efficiently or accumulating in vessel walls despite its moderate level. It measures blood pressure as a number but doesn’t reveal whether that pressure is driven by high ACE activity, impaired nitric oxide production, or sodium-aldosterone dysregulation — each of which responds differently to treatment.
Genetic testing fills that mechanistic gap. Knowing APOE status shapes LDL targets and dietary fat recommendations. Knowing ACE and NOS3 genotype informs which blood pressure interventions are most likely to work. Knowing F5 status changes the risk assessment for oral contraceptives, travel, and surgery. Knowing Lp(a) status — which is genetically fixed and doesn’t respond to statins — determines whether more aggressive cardiovascular screening is warranted even when standard markers look acceptable.
None of this replaces clinical care. A cardiologist or primary care physician should be the partner in translating genetic information into a prevention strategy. But arriving at that conversation knowing your genetic cardiovascular profile produces a fundamentally different, and more targeted, discussion than showing up with a cholesterol panel and a family history of “heart problems.”
Your Genetic Cardiovascular Profile
The SelfDecode Cardiovascular Health Report analyzes over 24 million genetic variants across 7 categories: Heart Health, Brain Vessels, Veins & Other Vessels, Heart Rate, Blood Pressure, Blood Lipids & Lab Markers, and Heart Health Genes. It delivers 81 genetic results covering conditions including coronary artery disease, stroke risk, atrial fibrillation, venous thromboembolism, and hypertension — examining genes including APOE, ACE, NOS3, F5, LPA, and MTHFR. Includes 50 personalized, DNA-based recommendations for diet, supplements, and lifestyle. Compatible with existing 23andMe and AncestryDNA raw data.